These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10754605)

  • 1. [Therapeutic time window in ischemic stroke].
    Katayama Y; Otsubo K
    J Nippon Med Sch; 2000 Apr; 67(2):139-42. PubMed ID: 10754605
    [No Abstract]   [Full Text] [Related]  

  • 2. Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
    Morris DC; Zhang L; Zhang ZG; Lu M; Berens KL; Brown PM; Chopp M
    Stroke; 2001 Nov; 32(11):2635-40. PubMed ID: 11692028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 4. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Van de Werf F
    J Am Coll Cardiol; 1993 Sep; 22(3):707-13. PubMed ID: 8354802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator].
    Verstraete M; Bory M; Collen D; Erbel R; Lennane RJ; Mathey D; Michels HR; Schartl M; Uebis R; Bernard R
    Klin Wochenschr; 1988; 66 Suppl 12():77-85. PubMed ID: 3126348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy for early reperfusion after stroke.
    Juttler E; Kohrmann M; Schellinger PD
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):656-63. PubMed ID: 17122798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic therapy for acute ischemic stroke: 3 h and beyond.
    Padma V; Fisher M; Moonis M
    Expert Rev Neurother; 2005 Mar; 5(2):223-33. PubMed ID: 15853492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strategy for circulatory disturbance].
    Uchiyama S; Yamazaki M; Iwata M
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1056-9. PubMed ID: 12235794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early patency in acute myocardial infarction.
    Belenkie I
    Can J Cardiol; 1993 Mar; 9(2):149-51. PubMed ID: 8490781
    [No Abstract]   [Full Text] [Related]  

  • 11. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of acute ischemic stroke].
    Minematsu K
    No To Shinkei; 2004 Nov; 56(11):921-6. PubMed ID: 15678948
    [No Abstract]   [Full Text] [Related]  

  • 14. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which thrombolytic agent should one choose?
    Topol EJ
    Prog Cardiovasc Dis; 1991; 34(3):165-78. PubMed ID: 1947122
    [No Abstract]   [Full Text] [Related]  

  • 16. tPA fast by GUSTO.
    Horton R
    Lancet; 1993 May; 341(8854):1188. PubMed ID: 8098084
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of streptokinase and tissue plasminogen activator on left ventricular function.
    White HD
    Adv Exp Med Biol; 1990; 281():383-7. PubMed ID: 2129375
    [No Abstract]   [Full Text] [Related]  

  • 18. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous hemarthrosis following thrombolytic therapy for acute myocardial infarction.
    Birnbaum Y; Stahl B; Rechavia E
    Int J Cardiol; 1993 Jul; 40(3):289-90. PubMed ID: 8225665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for acute ischemic stroke: new therapies on trial.
    Fisher M; Brott TG
    Stroke; 2003 Feb; 34(2):359-61. PubMed ID: 12574536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.